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Summary. Background: Activated factor XIII (FXIIIa), a
transglutaminase, introduces ﬁbrin–ﬁbrin and ﬁbrin–inhibitor
cross-links, resulting in more mechanically stable clots. The
impact of cross-linking on resistance to ﬁbrinolysis has proved
challenging to evaluate quantitatively. Methods: We used a
whole blood model thrombus system to characterize the role of
cross-linking in resistance to ﬁbrinolytic degradation. Model
thrombi, which mimic arterial thrombi formed in vivo,w e r e
prepared with incorporated ﬂuorescently labeled ﬁbrinogen, in
order to allow quantiﬁcation of ﬁbrinolysis as released
ﬂuorescence units per minute. Results: A site-speciﬁc inhibitor
of transglutaminases, added to blood from normal donors,
yielded model thrombi that lysed more easily, either spontane-
ously or by plasminogen activators. This was observed both in
the cell/platelet-rich head and ﬁbrin-rich tail. Model thrombi
fromanFXIII-deﬁcientpatientlysedmorequicklythannormal
thrombi; replacement therapy with FXIII concentrate normal-
ized lysis. In vitro addition of puriﬁed FXIII to the patients
preprophylaxisblood,butnottonormalcontrolblood,resulted
in more stable thrombi, indicating no further eﬃcacy of
supraphysiologic FXIII. However, addition of tissue transglu-
taminase, which is synthesized by endothelial cells, generated
thrombi that were more resistant to ﬁbrinolysis; this may
stabilize mural thrombi in vivo. Conclusions: Model thrombi
formed under ﬂow, even those prepared as plasma thrombi,
reveal the eﬀect of FXIII on ﬁbrinolysis. Although very low
levels of FXIII are known to produce mechanical clot stability,
a n dt oa c h i e v ec-dimerization, they appear to be suboptimal in
conferring full resistance to ﬁbrinolysis.
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Introduction
Activation by thrombin of the transglutaminase (TG) factor
XIII (FXIII) introduces cross-links into the ﬁbrin matrix,
dramatically altering its rheologic properties. The role of FXIII
in vivo is clear, deﬁciency resulting in bleeding, usually after a
delay, impaired wound healing and spontaneous abortion [1], a
phenotype echoed in FXIIIA-deﬁcient mice [2]. The human
recessive autosomal condition usually arises from mutations in
the A-subunit of FXIII [3], and is characterized in the
laboratory by soft plasma clots that are soluble in urea and
less mechanically stable [4]. Fibrin is a cofactor in FXIII
activation, forming a ternary complex with thrombin [5] and
facilitating release of the activation peptide and dissociation of
the carrier B-subunit [4] to form the active enzyme, FXIIIa. In
ﬁbrin, the initial reaction catalyzed by FXIIIa is between
Gln389/399 on one c-chain and Lys406 on another, generating
a c–c-dimer [6,7]. This is followed by generation of high
molecular mass polymers of the a-chain [7], with multimeric
cross-linked products of the c-chain occurring over extended
periods [8]. Another enzyme in the family, tissue TG (TG2)
occurs in erythrocytes and endothelial cells [9]. TG2 exhibits a
broader speciﬁcity than FXIIIa, catalyzing cross-linking
between c-chains and a-chains, and forming a-multimers in
both ﬁbrinogen and ﬁbrin [10].
FXIIIa contributes to clot stability by cross-linking
inhibitors of ﬁbrinolysis, primarily a2-antiplasmin (a2AP),
to ﬁbrin, decreasing the susceptibility of clots to lysis [11].
Plasminogen activator inhibitor (PAI)-2 [12] and thrombin-
activatable ﬁbrinolysis inhibitor (TAFI) [13] are substrates
for TGs, and can thus be incorporated into ﬁbrin. Despite
this body of evidence on cross-linked inhibitors, especially
a2AP [14], there has been variability in visualizing the effect
of FXIII in ﬁbrinolytic assays, with several studies showing
little, if any, effect [15–18], and others showing less efﬁcient
lysis of cross-linked clots [8,19–22]. Different explanations
have been given for these discrepancies [8,15], but there is a
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cross-linking on ﬁbrinolysis. Whole blood model thrombi
formed under ﬂow show a similar structure and protein
distribution to thrombi formed in vivo [23], and have revealed
the complementary nature of a2AP, PAI-1 and TAFI [24].
Here, we used model thrombi, and show that ﬁbrinolysis is
dramatically increased in FXIII deﬁciency, an effect that
could be recapitulated by incorporating a non-reversible
inhibitor of TGs.
Materials and methods
Blood collection and preparation of plasma
Peripheral blood was collected from consenting normal healthy
donors into a 0.1 volume of 0.13 M trisodium citrate; for some
experiments, platelet-free plasma was prepared [25] as a pool
from 15 normal individuals (pooled normal plasma). Blood
was also donated by a congenital homozygous FXIII-deﬁcient
patient (patient 1 in Anwar et al. [26]), characterized as having
truncated FXIIIA, the result of mutations within the splice-
donor sites. The patient was receiving routine prophylaxis with
approximately 10 U kg
)1 Fibrogammin
  P (Aventis, Paris,
France) at 4-weekly intervals, and blood samples were taken
before this treatment unless otherwise stated.
Thrombus formation and lysis
Thrombi were formed essentially as previously described
[27,28]. Brieﬂy, ﬂuorescein isothiocyanate (FITC)-labeled
ﬁbrinogen (75 lgm L
)1 ﬁnal concentration; FITC/ ﬁbrinogen
approximately 6 : 1) was added to citrated whole blood
(0.9 mL), and the system was recalciﬁed by addition of
10.9 mM CaCl2 in a total volume of 1.15 mL. A non-reversible
TG inhibitor, 1,3-dimethyl-2-[(2-oxopropyl) thio]imidazolium
chloride (1 mM) [29], FXIII (1 or 2.5 U mL
)1;F i b r o -
gammin P) or guinea pig TG2 (1, 2 or 4 U mL
)1;S i g m a -
Aldrich, Poole, UK) was added to blood prior to thrombus
formation. The same method was used to prepare thrombi
from platelet-free plasma. After rotation at a constant speed of
30 r.p.m. for 90 min at room temperature, thrombi were
removed from the serum and washed in 0.9% (w/v) NaCl.
T h r o m b iw e r et h e nb a t h e di n1 0m M Tris (pH 7.5) and 0.01%
Tween-20 containing tissue-type plasminogen activator (t-PA)
at 1 lgm L
)1 unless otherwise stated. In some experiments,
thrombi were incubated in buffer alone, to examine spontane-
ous lysis, or with 1 lgm L
)1 urokinase-type plasminogen
activator (u-PA). Thrombi were incubated at 37  C, samples of
the supernatant (5 lL) were removed at 0 min and at 30-min
intervals and diluted 1 : 50 in 10 mM phosphate and 150 mM
NaCl (pH 7.4), and the ﬂuorescence was then measured
(excitation 485 nm; emission 530 nm). In some experiments,
thrombi were bisected into cell-rich head and ﬁbrin-rich tail,
and lysed separately. Incorporation of FITC–ﬁbrinogen was
analyzed by lysing heads and tails to completion (18 h at 37  C
in 1 lgm L
)1 t-PA and 100 lgm L
)1 plasminogen).
FXIII activity assay
TG activity in plasma was quantiﬁed by using an adaptation of
two methods [30,31]. Human ﬁbronectin (5 lg per well) was
used to coat 96-well plates (CoStar; Corning, Lowell, MA,
USA). The FXIII standard was pooled normal plasma,
standardized against the international standard [32], preactivat-
ed with 1 U mL
)1 bovine thrombin at 37  Cf o r5 m i n .
Residual thrombin was neutralized by hirudin (2 lgm L
)1),
a n ds a m p l e sw e r ed i l u t e di n0 . 1M Tris (pH 7.4) and 1 mM
dithiothreitol (DTT), to construct a standard curve. Guinea pig
tissue TG (Sigma) activity was measured in the same way but
without prior thrombin treatment. The TG reaction, in 0.1 M
Tris (pH 7.4), 1 mM DTT, 5 mM CaCl2 and 0.5 mM 5-
(biotinamido)pentylamine (Pierce Thermo Fisher Scientiﬁc,
Rockford,IL,USA),wasstoppedafter2 hat37  Cbyaddition
of 2 mM EDTA in 0.1 M Tris (pH 7.4). Plates were washed and
blocked with 0.5% (w/v) milk powder for 30 min at 37  C, and
incorporated biotinylated amine was detected [30]. The assay
was linear for plasma FXIIIa between 2.5% and 100% normal,
prepared by mixing FXIII-deﬁcient plasma (Afﬁnity Biologi-
cals, Ancaster, Canada) and pooled normal plasma. The
coefﬁcient of variation was 7%, based on nine independent
assays of 50% normal plasma.
Sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE)
Cross-linked ﬁbrin was analyzed by clotting 10% (v/v) plasma
samples with ﬁnal concentrations of 15 mM cysteine, 8 mM
CaCl2 and 0.2 U mL
)1 thrombin in glass tubes [33]. Clots were
harvested after 30 min at 37  C by winding onto thin glass rods
(1.5 mm diameter), washed with 10 mM EDTA in 0.9% (w/v)
NaCl, dried in air, and dissolved in reducing buffer (10 min at
72  C, before separation on 4–12% polyacrylamide Bis–Tris
NuPAGE gels; Invitrogen, Karlsruhe, Germany). Degradation
products from plasma model thrombi,a f t e r4ho fl y s i s ,w e r e
analyzed under non-reducing conditions on the same gels. Gels
were stained with Coomassie Blue Brilliant R or immunoblot-
ted with antibody to the ﬁbrinogen c-chain (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Data analysis
Quantitative data are expressed as the mean and standard error
of the mean (n = at least 3). Data were analyzed in GRAPHPAD
PRISM 5 (GraphPad Software, La Jolla, CA, USA) and shown
as ﬂuorescence units (FU) released; rates of lysis (FU min
)1)
were determined by linear regression, and used to calculate fold
differences. Statistical analysis was performed by t-test, and P-
values < 0.05 were considered to be signiﬁcant.
Results
TGs stabilize model thrombi
Model thrombi were formed in the presence and absence of a
non-reversible TG inhibitor [29]. The inhibitor was used at
2018 N. J. Mutch et al
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constant, based both on the original work [29] and on our
analysis of its efﬁciency in inhibiting plasma FXIIIa activity,
where the IC50 was found to be 7 lM (data not shown).
Incorporation of TG inhibitor into the forming model
thrombus doubled the rates of lysis, relative to no inhibitor.
This was evident for lysis induced by t-PA (Fig. 1; 2.0-fold
increase in rate of lysis; P < 0.005) or u-PA (Fig. 1; 2.2-fold
increase; P < 0.001), present at 1 lgm L
)1 in the bathing ﬂuid
surrounding the washed thrombus. Model thrombi have
previously been shown to lyse spontaneously in the absence
of added plasminogen activators [34]. Inhibition of cross-
linking had less impact on spontaneous lysis (Fig. 1), but TG
inhibitor still increased the lysis rate signiﬁcantly (1.2-fold
increase; P <0 . 0 0 5 ) .
Model thrombi have a deﬁned structure, with a cell-rich and
platelet-rich head,and a ﬁbrin-rich tail[23]. Weseparately lysed
the heads and tails of model thrombi with t-PA (Fig. 2) or u-
PA (data not shown). These data are presented as percentage
lysis, because incorporation of FITC–ﬁbrinogen was found to
be consistently higher (about 1.5-fold) in heads than in tails, as
assessed by lysis to completion with t-PA and added plasmin-
ogen. TG inhibitor increased lysis of both heads (1.5-fold
increase) and tails (2.1-fold increase), both increases being
signiﬁcant (P < 0.005). Thus, the effect of cross-linking was
clear throughout the thrombus.
Stability of FXIII-deﬁcient thrombi
Blood samples were collected from a congenitally homozygous
FXIII-deﬁcient patient before and after routine FXIII admin-
istration. His preadministration plasma TG activity, after
activation with thrombin, was 8.8% ± 2.8% [mean ± stan-
dard deviation (SD)] of normal. Clots prepared from the
patient plasma and analyzed by SDS-PAGE were close to
normal in terms of c–c-dimer detection (Fig. 3A). Fully
deﬁcient commercial plasma or mixtures with < 3% normal
FXIII showed detectable c-monomer, as did normal plasma
treated with TG inhibitor.
Model thrombi prepared from the patients blood were lysed
more quickly by t-PA (4.4 ± 0.5 FU min
)1; n =4 ) t h a n
those from normal controls (2.7 ± 0.1 FU min
)1; n = 19;
P < 0.005). The effect of TG inhibitor on patient thrombi was
small, but still signiﬁcant (Fig. 3B; 1.1-fold increase;
P < 0.005). Thirty minutes after routine 4-weekly prophylaxis
with Fibrogammin (10 U kg
)1), plasma activity rose to
54.9% ± 7.9% of normal. The thrombi from post-FXIII
administration blood had normal rates of lysis
(2.9 ± 0.1 FU min
)1 vs. 2.7 ± 0.1 FU min
)1, respectively;
P = 0.08), and the greater effect of TG inhibition was restored
(Fig. 3; 1.8-fold increase; P < 0.005). Similar results were
achieved when different concentrations of t-PA and u-PA
(0.25–1 lgm L
)1) were used for lysis or for spontaneous lysis in
the absence of plasminogen activator (not shown). We then
formed thrombi from platelet-free plasma. Their lysis revealed
a 5.1-fold increase in lysis rate (Fig. 4A; P < 0.005) and a
signiﬁcant contrast between normal and FXIII-deﬁcient
plasma (5.6-fold increase; P < 0.005). Bathing ﬂuid harvested
after the ﬁnal time point (4 h) was analyzed by SDS-PAGE
and western blot. A change in the pattern of ﬁbrin degradation
products was observed, especially in terms of accumulation of
the D-monomer (90 kDa) band, which was present when the
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Fig. 1. Inhibition of cross-linking in thrombi. Thrombi were prepared in
the absence (s) or presence (d)o ft r a n s g l u t a m i n a s e( T G )i n h i b i t o ra n d
bathed in ﬂuid containing tissue-type plasminogen activator (t-PA;
1 lgm L
)1, n = 5), urokinase-type plasminogen activator (u-PA;
1 lgm L
)1, n = 4) or buﬀer alone (spontaneous, n =8 ) .L y s i sw a s
monitored as release of ﬂuorescence and expressed as mean ± standard
error of the mean. Diﬀerences in lysis rate with addition of TG inhibitor
were signiﬁcant (P < 0.01) in all cases.
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apparent, but at a lesser intensity, in bathing ﬂuid from the
patient plasma model thrombi (Fig. 4B).
Further stabilization of thrombi by addition of FXIII or tissue
TG
Addition of Fibrogammin to normal blood had no effect on
the stability of model thrombi (Fig. 5; P = 0.15), but addition
to FXIII-deﬁcient blood consistently made the thrombi more
resistant to lysis (Fig. 5; P < 0.001; 1.8-fold decrease). For
clarity, only the addition of 1 U mL
)1Fibrogammin to normal
blood is shown, but similar results were obtained with
2.5 U mL
)1. The data show that supraphysiologic levels of
FXIII produce no more resistance to lysis than normal levels.
Fibrin can also be cross-linked by TG2 with a pattern that is
distinct from that with FXIII [10,35]. To determine whether
TG2 could confer an additional degree of resistance to
ﬁbrinolysis, we added TG2 to normal blood (Fig. 5) at
concentrations equivalent to that of Fibrogammin, on the
basis of activity assay values. Such additions of TG2 caused
clear dose-dependent decreases in lysis, with reductions of 1.7-
fold, 2.1-fold and 2.6-fold for 1, 2 and 4 U mL
)1, respectively.
These differences were signiﬁcant (P < 0.005) relative to no
addition and for each concentration relative to the others.
These data show that TG2 stabilization of thrombi against
ﬁbrinolytic degradation supplements that caused by FXIIIa.
Discussion
A causal relationship between FXIII-dependent cross-linking
and decreased ﬁbrinolysis is predicted and often assumed, but
its quantitative demonstration in the laboratory has been
controversial [8,15–22]. This study reports the use of a ﬂow
model [23,24,28] to examine model thrombus lysis. Thrombi
were prepared with blood from an FXIII-deﬁcient patient,
which lysed much faster than thrombi from normal blood.
Similarly enhanced lysis was achieved by inhibiting cross-
linking in normal blood. We used a TG inhibitor that alkylates
the active site cysteine of the TGs without inﬂuencing other
thiol-sensitive enzymes [29], and is thus a more selective tool
than those that react with all cysteine groups, such as cystamine
or iodoacetamide, or chelate calcium ions [36]. Inclusion of TG
inhibitor during whole blood thrombus formation under ﬂow,
with shear rates equivalent to those found in larger arteries
(400–600 s
)1) [28], reproducibly doubledthe rate ofﬁbrinolysis.
The effect of TG inhibition was apparent in both heads and
tails of model thrombi, suggesting the importance of cross-
linking throughout the entire thrombus.
The data presented here demonstrate an effect of inhibiting
cross-linking on ﬁbrinolysis, whether t-PA or u-PA was used to
activate plasminogen, and also on the spontaneous lysis of
model thrombi, owing primarily to u-PA activity from
polymorphonuclear cells [34]. These cells have been shown to
degrade FXIII [37], but, clearly, sufﬁcient native FXIII remains
in model thrombi to achieve cross-linking. The concentration
of t-PA or u-PA (1 lgm L
)1) was chosen to reﬂect pharma-
cologic conditions and to avoid very high concentrations,
which result in inefﬁcient lysis [28], but the effects of neutral-
izing TG activity were also apparent at 250 ng mL
)1 t-PA and
when no activator was added (not shown). Our data expand
and quantify the observation made in 1966, in a similar ﬂow
system, with lysis assessed simply by inspection [19]. Formation
of thrombi under ﬂow has emerged from our studies as an
essential feature in revealing sensitivity to cross-linking. Parallel
studies using static clots, prepared with incorporated FITC–
ﬁbrinogen, have failed to show reproducible effects of cross-
linking; the same was true of turbidity assays [12,14,27] (not
shown). The observation that even plasma model thrombi,
formed under ﬂow, demonstrate sensitivity to cross-linking
greatly increases the utility and convenience of the model
system, allowing the use of stored plasma.
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thrombi were bisected into the platelet-rich head and ﬁbrin-rich tail before being lysed separately with tissue-type plasminogen activator (t-PA; 1 lgm L
)1).
Lysis was monitored as release of ﬂuorescence, and results are expressed as mean lysis (%) ± standard error of the mean (n = 4) relative to values
obtained when thrombi were lysed to completion with additional plasminogen and t-PA, as described in Materials and methods. Diﬀerences in percentage
lysis with addition of TG inhibitor were signiﬁcant (P < 0.005) for both heads and tails.
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  2010 International Society on Thrombosis and HaemostasisThe patient used in this study (patient 1 in [26]) is well
controlled by routine monthly prophylaxis with FXIII con-
centrate. He has had no spontaneous bleeds during the last
9 years. At the typical nadir of 8–9% normal plasma FXIII, c–
c-dimers were apparent in ﬁbrin prepared from his plasma.
Plasma clots from the same patient, some 25 years ago, when
he was treated less regularly and with fresh frozen plasma
rather than FXIII concentrate, had barely detectable c–c-
dimers [33]. Our model thrombus system shows clearly that 8–
9% normal plasma FXIII is not sufﬁcient to achieve normal
thrombus resistance tolysis, whereas the literature suggests that
trace levels of FXIII are adequate for normal hemostasis
[1,3,4]. Even at 8-9% FXIII activity, when stability of thrombi
was severely compromised, it was possible to detect the effect of
inhibiting TG, highlighting the exquisite sensitivity of our
system to cross-linking. Deﬁnitions of normality are inevitably
dependent on the methods used. The established view, that as
little as 5% FXIII is sufﬁcient, comes primarily from studies on
clotting [38]. Normality in terms of ﬁbrinolysis is not routinely
assessed, but Figure 1C shows clearly that spontaneous lysis is
sensitive to cross-linking. The challenge of exposing model
thrombi to pharmacologic concentrations of t-PA reveals a
requirement for higher levels of FXIII in this setting. The data
on the patient after administration of FXIII show that plasma
samples containing about 50% normal FXIII are indistin-
guishable from normal plasma in terms of model thrombus
stability. More detailed studies will be necessary to deﬁne
absolute requirements for FXIII in relation to different
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pre-transfusion and post-transfusion with FXIII (Fibrogammin P) on four separate occasions [as in (A)]. Thrombi were formed in the absence (open
symbols) or presence (closed symbols) of transglutaminase (TG) inhibitor, and lysed with tissue-type plasminogen activator (1 lgm L
)1). Lysis was
monitored as release of ﬂuorescence, and results are expressed as mean ± standard error of the mean (n = 4). Diﬀerences in lysis rate with addition of TG
inhibitor were signiﬁcant (P < 0.005) both pre-treatment and post-treatment.
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tional information will be useful in the context of FXIII being
used during surgery in patients with propensity for bleeding
[39,40].
The role of FXIII in enhancing the clot strength and
elasticity of ﬁbrin has been described extensively in static
clots [41–43]. A similar inhibitor to that used here has been
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plasminogen activator (1 lgm L
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inhibitor to plasma thrombi was signiﬁcant (P < 0.005), as was the
diﬀerence between the normal control and the patient (P < 0.005). (B)
After the ﬁnal time point (4 h), samples were taken from the bathing
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TG inhibitor or from the FXIII-deﬁcient patient (3). Samples were
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Fig. 5. Additional stabilization of normal and FXIII-deﬁcient blood.
Thrombi were formed from the whole blood of normal subjects or from
the patient deﬁcient in FXIII with the addition of FXIII or transgluta-
minase 2 (TG2). Thrombi were lysed with tissue-type plasminogen acti-
vator (1 lgm L
)1), and lysis was recorded as release of ﬂuorescence. The
normal control data in the top and bottom panels are mean
value ± standard error of the mean of 19 diﬀerent subjects. The diﬀerence
in lysis with addition of FXIII (1 U mL
)1 Fibrogammin P; d, m)w a sn o t
signiﬁcant in normal subjects (P =0 . 1 5 ,n = 3) but was signiﬁcant in
thrombi from FXIII-deﬁcient blood (P < 0.001, n = 3). Addition of
1Um L
)1 (d), 2 U mL
)1(m)a n d4Um L
)1 (j)T G 2( n =3 )r e s u l t e di n
signiﬁcantly less lysis (P < 0.005) relative to the normal control and each
concentration tested.
2022 N. J. Mutch et al
  2010 International Society on Thrombosis and Haemostasisshown to have a profound effect on clot rigidity [43]. Clot
strength is attributed largely to cross-linking of ﬁbrin
a-chains, the role of c-chain dimers being more controversial
[22,43,44]. Effects on lysis are even more variable, some
studies showing no or minor effects of cross-linking [15–18],
and others showing a relationship between cross-linking and
poorer lysis [8,19–22]. Assays of ﬁbrinolysis are well known
to show variable sensitivity to different components, depend-
ing on several factors, particularly the balance between
plasminogen activators and inhibitors [45], but also reﬂecting
ﬁbrinogen concentration [46], concentration and access of
plasminogen [47], and ionic strength [8]. It is not surprising,
therefore, that there is disagreement in the literature on the
effects of cross-linking on ﬁbrinolysis in vitro, but the impact
of TGs on ﬁbrinolytic resistance has been visualized in vivo
with the use of an experimental model of pulmonary
embolism [48]. Lysis of puriﬁed ﬁbrin was not affected by
c–c-dimers [21], whereas it was slowed by multimeric cross-
linking of a-chains [8] and the formation of c-multimers over
extended periods [49]. The products of lysis in this study
showed a clear band of D-monomer from patient samples or
when cross-linking in normal plasma was inhibited, but our
analysis was limited to samples taken after 4 h of lysis. This
study was not designed to distinguish between stabilization
resulting from ﬁbrin–ﬁbrin cross-links and those resulting
from ﬁbrin–inhibitor cross-links. Fibrin to which a2AP is
cross-linked lysed more slowly both in vitro [11,50], and
in vivo [48]. PAI-1, a2AP and TAFI all contribute to the
stability of cross-linked clots and thrombi [24]. The sensitivity
of model thrombi to different regulators of ﬁbrinolysis shows
its potential for deﬁning the contributions of ﬁbrin–ﬁbrin and
ﬁbrin–inhibitor cross-links to resistance to ﬁbrinolysis. Such
model thrombi may be useful in the study of a2AP
deﬁciency, as this inhibitor is markedly affected by cross-
linking status [11,50] and, indeed, occurs cross-linked to
ﬁbrinogen in plasma [51].
TG2 is known to catalyze cross-linking of ﬁbrin, with some
distinctions in the exact pattern as compared with FXIIIa
[9,10,35]. For this reason, we added TG2 to normal blood to
determine whether the ﬂow system was sensitive to the effects
of TGs other than FXIIIa. We found that supplementing
normal blood with TG2 produced thrombi that were more
resistant to lysis, demonstrating an additional degree of
ﬁbrinolytic resistance over that observed with endogenous
FXIII. Erythrocytes trapped within the ﬁbrin network have
been proposed as a source of TG2 [4], but our data imply
limited release during thrombus formation. In vivo, it is likely
that TG2 is present in mural thrombi, as it is an abundant
protein in the vessel wall [52] and can be upregulated by
thrombin [30]. It is noteworthy that active FXIIIa has a half-
life of 20 min in vivo a n dh a sb e e nr e p o r t e dt ob eaf e a t u r eo f
new thrombi [53] but constitutively active TG2 may stabilize
mature thrombi.
In conclusion, model thrombi prepared under ﬂow are
sensitive to the impact of cross-linking on ﬁbrinolytic resis-
tance. The system provides a convenient model in which to
address many remaining questions, such as role of cellular
FXIII, the inﬂuence of ﬁbrin vs. inhibitor cross-linking, and the
ability of different TGs to regulate these processes.
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